Literature DB >> 12616844

A model for the future conduct of pharmacovigilance.

Patrick C Waller1, Stephen J W Evans.   

Abstract

A scientific model to support excellence in pharmacovigilance has been developed from first principles by brainstorming sessions and discussions with experts in the field. The model represents a long-term vision of how pharmacovigilance could be conducted in the future. So far it has been developed without any consideration of constraints such as resources or the need for legislative change. Although the vision is holistic, it would be possible to test and implement parts of the model in a piecemeal fashion.

Mesh:

Year:  2003        PMID: 12616844     DOI: 10.1002/pds.773

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  38 in total

Review 1.  Pharmacovigilance of herbal medicines : a UK perspective.

Authors:  Joanne Barnes
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  Risk management : a European regulatory perspective.

Authors:  Jane N S Moseley
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 3.  CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.

Authors:  Panos Tsintis; Edith La Mache
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 4.  Current requirements and emerging trends for labelling as a tool for communicating pharmacovigilance findings.

Authors:  A Leander Fontaine
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 5.  The general practice research database: role in pharmacovigilance.

Authors:  Louise Wood; Carlos Martinez
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

6.  Prevention and pharmacovigilance: what should we do, what can we do?

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2012-02-01       Impact factor: 5.606

7.  Pharmacoepidemiology.

Authors:  Stephen J W Evans
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

8.  Pharmacovigilance.

Authors:  I Ralph Edwards
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

9.  Reflections on attribution and decisions in pharmacovigilance.

Authors:  Ola Caster; I Ralph Edwards
Journal:  Drug Saf       Date:  2010-10-01       Impact factor: 5.606

10.  A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.

Authors:  Peter G M Mol; Sabine M J M Straus; Sigrid Piening; Jonie T N de Vries; Pieter A de Graeff; Flora M Haaijer-Ruskamp
Journal:  Drug Saf       Date:  2010-06-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.